Karolinska Institutet and Cancer Research Horizons partnership launch event 15th of June 2023, 8.30-12.00
Karolinska Institutet and Cancer Research UK’s innovation engine, Cancer Research Horizons (CRH), have established a 5-year strategic partnership dedicated to accelerating the translation of academic cancer research into improved treatments for patients.
Working together, both KI and CRH will create a shared long-term strategy of promoting and supporting industry collaborations, and generation of new scientific discoveries that can be rapidly translated into the clinic.
Under the terms of this new partnership, the parties have committed to several joint activities including research collaborations and funding initiatives, theme-based alliances, mutual access to facilities, expertise, materials, and tools, as well as joint events, and training programmes.
On the 15th of June the partnership launch event will take place in Innomdicum auditorium Daggkåpan at Nanna Svartz väg 4. The event will start at 8.30 with networking and end at 12.00.
8.30-9.00 Morning coffee, sandwich, and networking
9.00-9.10 Welcoming words and opening of the partnership launch event
Prof. Martin Bergö Vice President of Karolinska Institutet and Richard Cowburn, Head of External Engagement Office KI
9.10-9.45 Cancer Research Horizon
Julie Little Associate Director CRH, Strategic Alliances
9.45-10.05 Cancer Research KI
Prof. Simon Ekman, Cancer Research KI
10.05-10.25 Karolinska Insitutet strategic alliances
Richard Cowburn, Head of External Engagement Office KI
10.25-10.40 Short Break
10.40-11.10 Case study – how to collaborate with industry and creating value.
11.10-11.40 Tools Company
11.40-12.00 Discussion and further questions
Opportunity to sign-up for on-to-one meetings (June 15, afternoon)
The partnership also provides the mechanism for Karolinska Institutet researchers to access the Cancer Research Horizons AstraZeneca Antibody Alliance Lab (“AAL”)* to use AstraZeneca’s phage display technology to undertake drug discovery research on novel cancer targets.
*Cancer Research Horizons AstraZeneca Antibody Alliance Lab is a standalone laboratory which brings together the combined strength of Cancer Research Horizon's cancer biology expertise with the world-class antibody engineering technology of AstraZeneca to support your novel antibody discovery projects. A team of 20 drug discovery and antibody engineering scientists are experts in antibody phage display and associated technologies, and in the expression and purification of high-quality proteins.
In the afternoon of the 15th of June, the team from CRH will be available for one-to-one meetings to discuss specific interests of the cancer researchers at KI on the collaboration and particularly on the Cancer Research Horizons AstraZeneca Antibody Alliance Lab (“AAL”). There are limited spots available,please express your interest in the one-to-one meeting in the registration form. Several researchers will be selected and contacted closer to the date.